KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Non-Current Liabilities: 2019-2025

Historic Other Non-Current Liabilities for Esperion Therapeutics (ESPR) over the last 5 years, with Sep 2025 value amounting to $7.4 million.

  • Esperion Therapeutics' Other Non-Current Liabilities was N/A to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year change of. This contributed to the annual value of $239.9 million for FY2023, which is 9.64% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Other Non-Current Liabilities is $7.4 million, which was down 0.00% from $7.4 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Other Non-Current Liabilities high stood at $265.0 million for Q3 2022, and its period low was $7.4 million during Q2 2025.
  • Over the past 3 years, Esperion Therapeutics' median Other Non-Current Liabilities value was $230.4 million (recorded in 2023), while the average stood at $169.1 million.
  • In the last 5 years, Esperion Therapeutics' Other Non-Current Liabilities soared by 45.73% in 2021 and then fell by 13.08% in 2023.
  • Over the past 5 years, Esperion Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $245.7 million in 2021, then dropped by 10.95% to $218.8 million in 2022, then grew by 9.64% to $239.9 million in 2023, then rose by 5.11% to $236.4 million in 2024, then reached $7.4 million in 2025.
  • Its Other Non-Current Liabilities stands at $7.4 million for Q3 2025, versus $7.4 million for Q2 2025 and $236.4 million for Q1 2024.